Home » Stocks » GNMK

GenMark Diagnostics, Inc. (GNMK)

Stock Price: $14.05 USD 0.26 (1.89%)
Updated December 4, 4:00 PM EST - Market closed

GNMK Stock Price Chart

Key Info

Market Cap 1.01B
Revenue (ttm) 148.67M
Net Income (ttm) -25.21M
Shares Out 71.10M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $14.05
Previous Close $13.79
Change ($) 0.26
Change (%) 1.89%
Day's Open 13.79
Day's Range 13.59 - 14.16
Day's Volume 357,917
52-Week Range 3.49 - 19.10

GNMK Stock News

GlobeNewsWire - 4 weeks ago

CARLSBAD, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testi...

Seeking Alpha - 1 month ago

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 month ago

CARLSBAD, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced f...

Zacks Investment Research - 1 month ago

GenMark Diagnostics (GNMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

CARLSBAD, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on W...

InvestorPlace - 1 month ago

GenMark Diagnostics just received emergency approval for its coronavirus test panel. GNMK stock is soaring as a result.

GlobeNewsWire - 1 month ago

Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season Combination test for COVID-19, flu and other common respiratory...

CNBC - 1 month ago

Tests that can screen for the flu, the coronavirus and other pathogens could be crucial in combating Covid-19 and influenza this winter, public health specialists say.

GlobeNewsWire - 1 month ago

Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth Third Quarter 2020 Revenue Expected to Represent Approximately 104% Year-Over-Year Growth

Zacks Investment Research - 2 months ago

Investors need to pay close attention to GenMark Diagnostics (GNMK) stock based on the movements in the options market lately.

GlobeNewsWire - 2 months ago

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens helps health care professionals prepare for flu season

Benzinga - 3 months ago

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.

Other stocks mentioned: CODX, QDEL
The Motley Fool - 3 months ago

Blame it on Abbott.

Other stocks mentioned: CODX, LMNX, OPK
GlobeNewsWire - 3 months ago

Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity

Seeking Alpha - 3 months ago

Investing For The Long Run: Navigating A Bifurcated Market

Other stocks mentioned: ABBV, EMN, ENB, EPD, MO, MSFT, PRU, TDOC
Seeking Alpha - 3 months ago

Most medical diagnostic and research companies tend not to be involved in the COVID-19 virus vaccine race, but entries who are need tools to speed their pace.

Seeking Alpha - 4 months ago

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q2 2020 Results - Earnings Call Transcript

Benzinga - 4 months ago

Shares of GenMark Diagnostics (NASDAQ:GNMK) moved lower by 6.81% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 4 months ago

CARLSBAD, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced...

GlobeNewsWire - 4 months ago

CARLSBAD, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced ...

Zacks Investment Research - 4 months ago

Is (GNMK) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 4 months ago

CARLSBAD, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close o...

Zacks Investment Research - 4 months ago

Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.

Other stocks mentioned: CODX, IMMU
Seeking Alpha - 4 months ago

Mike Cintolo is a leading growth stock expert and is the editor of Cabot Top Ten Trader.

Other stocks mentioned: NVTA
Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in GenMark Diagnostics.

CNBC - 4 months ago

We used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts.

Other stocks mentioned: COST, WORK, ANGI, SYNA
The Motley Fool - 4 months ago

Investors liked the company's preliminary Q2 results.

Investors Business Daily - 4 months ago

Coronavirus test maker GenMark Diagnostics soared to a record high after second-quarter sales shattered expectations. GenMark has quadrupled in 2020 in the face of the Covid-19 pandemic.

GlobeNewsWire - 4 months ago

Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth

GlobeNewsWire - 5 months ago

Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow Updated test provides rapid results for SARS-CoV-2 and other important re...

Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor of GenMark Diagnostics

Zacks Investment Research - 5 months ago

GenMark Diagnostics (GNMK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 5 months ago

Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections Largest health system in eastern North Carolina...

Zacks Investment Research - 6 months ago

GenMark Diagnostics has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 6 months ago

GenMark Diagnostics (GNMK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Motley Fool - 6 months ago

A coronavirus diagnostic test is fueling this biotech's revenue for 2020.

GlobeNewsWire - 6 months ago

CARLSBAD, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercial...

Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for May 8th

Other stocks mentioned: CGEN, CHGG
Zacks Investment Research - 6 months ago

Top Ranked Momentum Stocks to Buy for May 7th

Other stocks mentioned: CLX, MKTX
GlobeNewsWire - 6 months ago

CARLSBAD, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercial...

GlobeNewsWire - 6 months ago

CARLSBAD, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercial...

Seeking Alpha - 7 months ago

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

GenMark Diagnostics (GNMK) delivered earnings and revenue surprises of 75.00% and 0.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

GlobeNewsWire - 7 months ago

CARLSBAD, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced ...

The Motley Fool - 7 months ago

Investors appear to have high hopes for the company's COVID-19 diagnostic test sales as states move toward reopening their economies.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to GenMark (GNMK) stock based on the movements in the options market lately.

24/7 Wall Street - 7 months ago

GenMark Diagnostics Inc. (NASDAQ: GNMK) shares shot up early on Wednesday after the company provided an update on its quarterly numbers and where it stands with its coronavirus test.

GlobeNewsWire - 7 months ago

First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth

GlobeNewsWire - 8 months ago

CARLSBAD, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced...

24/7 Wall Street - 8 months ago

GenMark Diagnostics Inc. (NASDAQ: GNMK) may not be a household name, and most investors are not aware of it, with its market cap of just under $300 million.

About GNMK

GenMark Diagnostics, a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom m... [Read more...]

Industry
Medical Devices
IPO Date
May 28, 2010
CEO
Scott Mendel
Employees
437
Stock Exchange
NASDAQ
Ticker Symbol
GNMK
Full Company Profile

Financial Performance

In 2019, GNMK's revenue was $88.02 million, an increase of 24.40% compared to the previous year's $70.76 million. Losses were -$47.35 million, -6.24% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for GNMK is 20.60, which is an increase of 46.62% from the latest price.

Price Target
$20.60
(46.62% upside)